We report two patients with RubinsteinTaybi syndrome out of a total of 16 tested who have a deletion ofthe region visualised by the cosmid probe RT1. These results further confirm this as a locus for Rubinstein-Taybi syndrome. (JrMed Genet 1996;33:82-83) Using the RT1 probe we investigated a group of British patients with Rubinstein-Taybi syndrome to ascertain how many of them had a similar microdeletion. All the patients had been examined by at least two clinical geneticists and confirmed as having Rubinstein-Taybi syndrome clinically. There were six female and 10 male patients; two of the female patients were twins.
Rubinstein-Taybi syndrome (RTS) was first described in 1963' and is a well recognised dysmorphic syndrome causing mental handicap. It has been suggested that the condition probably occurred as an autosomal dominant mutation, either as a submicroscopic deletion or duplication or as a point mutation. 2 The second patient was also male with no cytogenetic abnormality and the typical phenotype, with features similar to the first patient. Both parents were checked using the RT 1 probe and neither was found to be deleted. In each case therefore the deletion appears to be a de novo event.
Rubinstein-Taybi syndrome characteristically comprises broad thumbs and halluces, distinctive facial dysmorphism, growth retardation, and mental handicap. It has, until now, been a diagnosis based on clinical criteria only and the availability of a new test may help clarify the diagnosis where there is some uncertainty. However, when the RT1 probe has been used, only a maximum of 25% of clinically unequivocally diagnosed patients have been found to have a deletion. It may be that in some patients their deletion is too small to be detected by the probe or that the cause of the RTS phenotype in them is a point mutation. Another possibility is that RTS is heterogeneous. Uniparental disomy for chromosome 16 has been excluded previously in one group of patients.8 Clinically, there appears to be no obvious difference between those patients who are deleted and those who are not in our series.
As the region encompassed by the probe is better defined, the genes involved in the microdeletion will be elucidated and further understanding of the phenotype expression achieved. The RT1 probe will be a useful adjunct to clinical diagnosis and continued cytogenetic study of patients with RTS will be useful to look for evidence of heterogeneity.
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